Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma

Cancer

Volumn 77, Issue 6, 1996, Pages 1066-1072

  Picardo, Antonio L ^a   Díez, Manuel ^a   Torres, Antonio ^a   Maestro, Marisa ^a   Ortega, Dolores ^a   Hernando, Florentino ^a   Gómez, Ana ^a   García Asenjo, Jose ^a   Balibrea, Jose L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

CA 125; Carcinoembryonic antigen; Lung cancer; Prognostic factors; Squamous cell carcinoma antigen; Tumor markers

Indexed keywords

ANTIGEN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CYTOSOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029925080     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960315)77:6<1066::aid-cncr10>3.0.co;2-%23     Document Type: Article

References (21)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott, 1993:673-758.
2. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-8.
3. Niiranen A, Niitamo-Korhonen A, Kouri M, Assendelft A, Mattson K, Pyrhönen S. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: A randomized study. J Clin Oncol 1992;10:1927-32.
4. Feld R, Rubinstein L, Thomas PA, Group TLCS. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completed resected Stage I non-small-cell lung cancer. J Natl Cancer Inst 1993;85:299-306.
5. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96: 440-7.
6. Lee JS, Hong WK. Prognostic factors in lung cancer [Editorial]. N Engl J Med 1992;327:47-8.
7. Linnoila I. Pathology of non-small cell lung cancer: New diagnostic approaches. Hematol Oncol Clin North Am 1990;4:1027-49.
8. Carney DN. Lung cancer biology. Eur J Cancer 1991;27:366-9.
9. Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 1992;69:1592-9.
10. Diez M, Ortega MD, Maestro ML, Torres A, Gómez A, Hernando F, et al. Relationship between serum and cytosolic concentrations of CEA, CA 125 and SCC antigens in patients with non-small cell lung cancer. J Tumor Marker Oncol 1994;9:25-30.
11. Concannon JP, Dalbow MH, Hodgson SF, Headings JJ, Markopoulos E, Mitchell J, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer 1978;42:1477-83.
12. Buccheri GF, Ferrigno D, Sartors AM, Ferrigno D, Curcio A, Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986;57:2389-95.
13. Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL. Evaluation of serum CA 125 as a tumor marker in non-small-cell lung cancer. Cancer 1991;67:150-4.
14. Picardo AL, Torres AJ, Maestro M, Ortega D, García-Asenjo J, Mugùerza J, et al. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125 and CA 50 cytosolic content in non-small cell lung cancer. Cancer 1994;73:2305-11.
15. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S.
16. Kayser K, Bülzebruck H, Probst G, Vogt-Moykopf I. Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients. Cancer 1987;59:355-60.
17. Chung CK, Zaino R, Stryker JA, O'Neill M, DeMuth WE. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg 1981;33:599-608.
18. Díez M, Torres A, Pollán M, Gómez A, Ortega D, Maestro M, et al. Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer 1994;73:1368-76.
19. Body IJ, Sculier JP, Raymarkers N, Paesmans M, Ravez P, Libert P, et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 1990;65:1552-61.
20. Sorensen JB, Hirsch FR, Gazdar A, Olsen JE. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer 1993;71:2971-6.
21. Benfield JR, Wain JC, Derrick M, Smith S, Ohnuki Y, Bates S, et al. Biochemical and cytogenetic studies of human lung cancers. J Thorac Cardiovasc Surg 1988;96:840-7.